<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00307450</url>
  </required_header>
  <id_info>
    <org_study_id>TUD-LELEDY-007</org_study_id>
    <secondary_id>Ethic board no.: EK10012006</secondary_id>
    <secondary_id>EUDRAC no.: 2005-005940-18</secondary_id>
    <nct_id>NCT00307450</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease</brief_title>
  <acronym>LeLeDys</acronym>
  <official_title>Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease (LeLeDys Study) - A Multicenter, Randomized, Stratified, Double-blinded, Placebo-controlled Phase IV Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to measure the efficacy and safety of levetiracetam on levodopa-induced
      dyskinesias in late-stage Parkinson's disease. The patients are planned to be treated with
      levetiracetam (up to 2000 mg per day) or placebo for 13 weeks. Efficacy measure is the
      modified AIMS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The LeLeDys study is designed to determine the efficacy and safety of levetiracetam on
      levodopa-induced dyskinesias in advanced Parkinson's disease.

      The design is a multicenter, randomized, stratified, double-blinded, placebo-controlled phase
      IV study design.

      The hypothesis is that levetiracetam is able to reduce duration and severity of
      levodopa-induced dyskinesias in Parkinson's disease.

      The patients are planned to be treated with levetiracetam (up to 2000 mg per day) or placebo
      for 13 weeks. Efficacy measure is the modified AIMS.

      Main inclusion criteria are:

        -  Advanced Parkinson's disease (Hoehn &amp; Yahr II-IV)

        -  Age of 30 to 80 years

        -  Levodopa-induced dyskinesias of at least 25% of the waking day and with moderate
           disability

        -  Stable dosage of antiparkinson medication and/or stable deep brain stimulation
           parameters for at least 4 week prior inclusion

        -  Written informed consent

      Main exclusion criteria are:

        -  Atypical parkinsonian syndromes

        -  Treatment with antipsychotics

        -  Epilepsia or seizure in the history

        -  Deep brain stimulation other than DBS in STN

        -  Pregnant or lactating women

        -  Severe dementia

      Methods:

        -  Primary outcome measure is the modified AIMS

        -  Secondary outcome measures include UPDRS, safety, patient day record

      Study medication:

        -  Levetiracetam (upt to 2000 mg / day)

        -  Matched Placebo
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified AIMS</measure>
    <time_frame>11 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>UPDRS items 32 &amp; 33</measure>
    <time_frame>11 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>UPDRS</measure>
    <time_frame>11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schwab &amp; England scale</measure>
    <time_frame>11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hoehn &amp; Yahr scale</measure>
    <time_frame>11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GCI</measure>
    <time_frame>11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient day record</measure>
    <time_frame>11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epsworth sleep scale</measure>
    <time_frame>11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levodopa challenge test</measure>
    <time_frame>11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measures</measure>
    <time_frame>11 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Parkinson's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <description>up to 200 mg per day in two dosages per day.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced Parkinson's disease (Hoehn &amp; Yahr II-IV)

          -  Age of 30 to 80 years

          -  Levodopa-induced dyskinesias of at least 25% of the waking day and with moderate
             disability

          -  Stable dosage of antiparkinson medication and/or stable deep brain stimulation
             parameters for at least 4 week prior inclusion

          -  Written informed consent

        Exclusion Criteria:

          -  Atypical parkinsonian syndromes

          -  Treatment with antipsychotics

          -  Epilepsia or seizure in the history

          -  Deep brain stimulation other than DBS in STN

          -  Pregnant or lactating women

          -  Severe dementia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Storch, M</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technical University of Dresden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology at the Technical University of Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology at the University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.neurodegeneration-dresden.de</url>
  </link>
  <link>
    <url>http://www.neuro.med.tu-dresden.de</url>
  </link>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2006</study_first_submitted>
  <study_first_submitted_qc>March 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2006</study_first_posted>
  <last_update_submitted>July 31, 2009</last_update_submitted>
  <last_update_submitted_qc>July 31, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. med. Alexander Storch</name_title>
    <organization>Dresden University of Technology</organization>
  </responsible_party>
  <keyword>Dyskinesias</keyword>
  <keyword>Parkinson's disease</keyword>
  <keyword>Levetiracetam</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

